BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TAK-168 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TAK-168\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06994806-11366@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:TAK-168: Phase 1 readout est. (NCT06994806)
DESCRIPTION:TAK-168\, phase 1.\nStudy: A Study to Investigate the Safety an
 d Efficacy of KQB168 as Monotherapy and in Combination in Participants Wit
 h Advanced Solid Malignancies\nEstimated primary completion: 30 November 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tak-168#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06994806
URL:https://assetmemo.bio/drug/tak-168#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
